a. Molecular Profile
●Type: GLP-1 receptor agonist.
●Structure: Semaglutide is a modified form of GLP-1 with enhanced stability and efficacy, achieved by substituting amino acids to extend its half-life.
b. Mechanism of Action
●Binds to GLP-1 receptors in the pancreas and brain.
●Stimulates insulin release and inhibits glucagon secretion.
●Delays gastric emptying, reducing food intake and promoting weight loss.
c. Administration
●Available as a subcutaneous injection, typically administered once weekly.
●Oral formulations are also available, though less common in fitness applications.
d. Safety Profile
●Generally well-tolerated when used as directed.
●Common side effects include mild gastrointestinal discomfort, which tends to subside with continued use.






